<DOC>
	<DOCNO>NCT02259582</DOCNO>
	<brief_summary>A randomized , double-blind , 3-arm ( 1:1:1 ) study subject first-line Stage IV non-squamous NSCLC . The purpose test efficacy safety demcizumab , give combination carboplatin pemetrexed compare placebo . The administration carboplatin pemetrexed standard treatment patient non-squamous non-small cell lung cancer .</brief_summary>
	<brief_title>A Study Carboplatin , Pemetrexed Plus Placebo v Carboplatin , Pemetrexed Plus 1 2 Truncated Courses Demcizumab Subjects With Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Patients enrol center North America , Western Europe , Australia New Zealand . Up 28 day ( 4 week ) prior treatment . If enrol study , receive intravenous ( vein ) infusion demcizumab ( placebo ) , carboplatin , pemetrexed administer day , every 21 day 4 cycle , show cancer gotten bad . If physician decides delay treatment one agent due side effect , agent may still administer schedule . After 4 cycle , stable improve disease , continue receive pemetrexed every 21 day maintenance therapy . After 8 cycle , stable improve disease , may receive demcizumab ( placebo ) , every 21 day 4 cycle . You undergo assessment every 6 week determine status disease .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Main 1 . Signed Informed Consent Form 2 . Histologically cytologically confirm Stage IV nonsquamous NSCLC 3 . Availability FFPE tumor tissue , either fresh coreneedlebiopsied archived 4 . Age &gt; = 21 year 5 . ECOG performance status 0 1 6 . Disease measurable per RECIST v1.1 7 . Adequate organ marrow function 8 . For woman childbearing potential , agreement use two effective form contraception Main 1 . Histologically cytologically document , advance , mixed nonsmall cell small cell tumor mix adenosquamous carcinoma 2 . NSCLC known EGFR mutation anaplastic lymphoma kinase ( ALK ) gene translocation ( EML4ALK ) 3 . Prior ongoing therapy ( include chemotherapy , antibody therapy , tyrosine kinase inhibitor , radiotherapy , immunotherapy , hormonal therapy , investigational therapy ) treatment Stage IV nonsquamous NSCLC 4 . Evidence tumor invade major blood vessel , cavitation one pulmonary tumor mass ( e ) ortracheoesophageal fistula 5 . Brain metastasis , leptomeningeal disease , uncontrolled seizure disorder , active neurologic disease 6 . Malignancies nonsquamous NSCLC successfully treat within 3 year prior randomization ( exception certain earlystage cancer ) 7 . History significant allergic reaction attribute humanized human monoclonal antibody therapy 8 . Significant intercurrent illness define illness may result subject 's death prior death nonsquamous NSCLC and/or significantly limit ability comply requirement study 9 . Recent hemoptysis &gt; 2.5 mL serious bleed another site , know bleed disorder coagulopathy therapeutic anticoagulation 10 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomization , anticipation need major surgical procedure course study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>histologically</keyword>
	<keyword>confirm</keyword>
	<keyword>malignancy</keyword>
	<keyword>metastatic</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>carboplatin</keyword>
	<keyword>carcinoma</keyword>
	<keyword>non small cell lung</keyword>
	<keyword>lung neoplasm</keyword>
	<keyword>lung disease</keyword>
</DOC>